News und Analysen
Sensorion appoints Aniz Girach as Independent Board Member
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces that the
Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB)
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that it has entered into a €15 million
Lysogene Awarded Innovation Passport by the UK MHRA for the GM1 Gangliosidosis Program
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today that the Medicines and
Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...
ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60
ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3.60 Per Share
Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for
Valbiotis meldet die Einreichung von drei klinischen Protokollen für den zur Blutdrucksenkung indizierten Wirkstoff TOTUM•854 bei den zuständigen Behörden und stellt seinen Plan für eine umfassende klinische Entwicklung vor
Pflichtmeldung:
Valbiotis (FR0013254851 – ALVAL, PEA/SME-qualifiziert) (Paris:AVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation
EQS-Adhoc: Veränderung im Verwaltungsrat von Newron
EQS-Adhoc: Change in Newron Board of Directors
DGAP-Adhoc: Veränderung im Verwaltungsrat von Newron
Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:AVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Nova Mentis Life Science Completes Acquisition of Pilz Bioscience
Vancouver, British Columbia – December 1, 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that, further to its
Nova Mentis Life Science schließt Übernahme von Pilz Bioscience ab
Vancouver, British Columbia – 1. Dezember 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FWB: HN3Q) (OTCPK: LIBFF) („NOVA“ oder das „Unternehmen“) freut sich bekannt zu geben, dass im
Sirona Biochem veröffentlicht Schreiben des CEO an die Aktionäre
Vancouver, Canada – November 30, 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to provide an update from the Company’s CEO, Dr. Howard Verrico.
Sirona Biochem Releases CEO Letter to Shareholders
Vancouver, Kanada – 30. November 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (US-OTC: SRBCF) („Sirona“) freut sich, ein Update von Dr. Howard J. Verrico, dem CEO des Unternehmens, zu
True Leaf informiert über aktuellen Stand des Handelsverbots für das Management
Vernon (BC), 23. November 2020. True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FWB: TLA) („True Leaf“ oder das „Unternehmen“) stellt diesen zweiwöchentlichen Statusberichts im Einklang
True Leaf Provides Management Cease Trade Order Update
Vernon, BC - November 23, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLA) (“True Leaf” or the “Company”) is providing a biweekly default status report in accordance with
Relay Medical & Fio Announce Pilot for COVID-19 Rapid Testing with Lonestar Life Sciences at Rural Hospitals in Texas
November 20, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”), together Fionet Rapid Response Group (“FRR”) are
Relay Medical & Fio melden Pilotprojekt für COVID-19-Schnelltests mit Lonestar Life Sciences in ländlichen Krankenhäusern in Texas
20. November 2020 - Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“) freuen sich, gemeinsam mit der Fionet Rapid
Relay Medical & Fio to Bring Fionet Mobile COVID-19 Testing & Tracking Platform to Private School Campus and Hockey Rink in the Greater Toronto Area
November 18, 2020 – Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”), together Fionet Rapid Response Group (“FRR”) report
Relay Medical & Fio versorgen privaten Schulcampus und Hockeyplätze im Großraum Toronto mit mobiler COVID-19-Test- & Trackingplattform Fionet
18. November 2020 – Relay Medical Corp. („Relay“ oder das „Unternehmen“) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) und Fio Corporation („Fio“), die zusammen als Fionet Rapid Response Group („F